Lv4
560 积分 2025-08-13 加入
Comparison of the effectiveness and safety of GLP-1receptor agonists for type 2 diabetes mellituspatients with overweight/obesity:A systematicre艨廍冀权i袞需e猹褂亲w and network meta-analysis
10个月前
已关闭
Efficacy and Safety of Glucagon-Like Peptide-l ReceptorAgonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials
10个月前
已完结
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study
10个月前
已完结
IDF21-0323 Safety and efficacy of IBI362 (LY3305677) in Chinese patients with T2D: A randomized, placebo-controlled phase 1b study
10个月前
已完结
Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)
10个月前
已关闭
- Safety and Efficacy of IBI362 (LY3305677) 9mg and 10 mg in Chinese Adults with Overweight or Obesity
10个月前
已完结
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
11个月前
已完结
Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials
11个月前
已完结
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
11个月前
已完结
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
11个月前
已完结
皖公网安备34019202002308
